Nichi GLOW: Japanese beta-glucan improves behavior, sleep and gut microbiome in children with autism spectrum disorder in clinical study

0

Content of the article

Controlling enterobacteriaceae, a cause of the disease, may help fight Parkinson’s and Alzheimer’s disease

Content of the article

TOKYO – In the first report of its kind, children with autism spectrum disorders (ASD) showed improved behavior, learning abilities and sleep, after oral consumption of AFO-202 strain of black yeast Aureobasidium Pullulans product of beta 1,3 -1,6 glucan (Nichi GLOW), published in BMJ Neurology Open (http://dx.doi.org/10.1136/bmjno-2021-000203). Beneficial replenishment of the gut microbiota has also been reported with Nichi GLOW, which differs from other beta-glucans in its source, method of production and purity.

The improvement in behavior in autistic children after a 90-day intake of Japanese beta-glucan Nichi GLOW, which may have prophylactic potential in neurodegenerative diseases like Parkinson’s disease and Alzheimer’s disease, deserves clinical validation in as a complement.

Autism is a neurodevelopmental disorder affecting 1 in 44 children in the developed world, with multiple causes and varying severity of manifestations. These children are more likely to develop neurodegenerative diseases later in life. In the study, Nichi GLOW intake improved CARS score and communication skills ( https://www.youtube.com/watch?v=reJOjBMKSg4). Nichi GLOW controlled Enterobacteriaceae, a gut microbiome that produces harmful proteins like curli and amyloid, leading to misfolding and aggregation of alpha-synuclein in neurons, a cause of the disease (https://doi. org/10.1101/2021.10.26.21265505). Synucleinopathy spreading through the gut-brain axis to the brain, could cause Parkinson’s disease or dementia, therefore, it is worth studying the prophylaxis of the Nichi Glucan product line in neurodegenerative conditions, as activation of microglia is one mechanism of their action in the brain (https://doi.org/10.1016/j.jns.2021.117554), explains lead researcher Dr. Raghavan.

The results were presented in a webinar commemorating autism sunday ( https://www.ncrmniche.org/autismsunday2022/proceedings/index.html), organized by the Jesuit Interdisciplinary Center Antonyraj memorial for Advanced Recovery and Education (JAICARE). Research conducted in Japan has revealed the hidden potentials ( https://doi.org/10.1101/2021.08.05.21261640), of this ß-glucan; thanks to a healthy ecosystem in Japan assisting in the development of new solutions, which together with GN Corp’s cross-global interdisciplinary network of healthcare expertise, made this groundbreaking feat possible, the scientists commented. https://sponsored.bloomberg.com/article/jco/japan-where-high-tech-meets-high-value-foreign-direct-investment

The Nichi Glucan product line was approved as a food additive in Japan in 1996 and does not contain any commonly notified allergens. They are unique, being produced as an exo-polysaccharide by new strains of Aureobasidium Pullulans in a GMP certified facility in Japan and exported under various brands: Nichi-GLOW, Neu-REFIX, Nichi Glucan & Nichi Glucan-REFIX; not intended to diagnose, treat, cure or prevent any disease and approval status may vary from country to country. The publications are intended for academic purposes and research initiative; should not be construed as medical advice. A doctor’s advice is recommended for specific health issues.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220313005031/en/

logo

contacts

Samuel JK Abraham
info@gncorporation.com

#distro

Share.

Comments are closed.